KEY POINTS
1. HSCT after PD-1 blockade is feasible although may be associated with increased early immune toxicity.
PD-1 blockade may cause persistent depletion of PD1
+ T-cells and alterations in T-cell differentiation impacting subsequent treatment.
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INTRODUCTION
Programmed cell death protein 1 (PD-1) is an inhibitory receptor expressed on activated T cells and other lymphoid and myeloid cells. The PD-1 synapse is an important mechanism by which malignancies can evade the host immune response 1, 2 . Clinical trials of anti-PD-1 monoclonal antibodies (mAbs) have demonstrated promising results in lymphoma patients with advanced disease. Hodgkin lymphoma (HL), which appears to have a unique biologic dependence on the PD-1 pathway, is particularly susceptible to PD-1 blockade 3, 4 and one PD-1 inhibitor, nivolumab, was recently approved by the FDA for treatment of classical HL 5 . Clinical activity has also been observed in several subtypes of non-Hodgkin lymphoma (NHL) 6, 7 .
Given the success of these agents in early studies, anti-PD-1 mAbs are being tested alone and in combination in a growing number of clinical trials across many hematologic malignancies. Many participants in these trials will at some point become potential
candidates for allogeneic hematopoietic stem cell transplantation (HSCT); however, the safety and efficacy of HSCT may be different in patients previously exposed to PD-1 inhibitors, given their immunomodulatory mechanism and their prolonged clinical activity 8 . Specifically, residual PD-1 inhibition peri-and post-HSCT could enhance allogeneic T-cell responses, which could augment the graft-versus-tumor (GVT) effect but also increase the incidence or severity of immune complications. Animal models demonstrate that PD-1 blockade early after allogeneic HSCT may augment GVT in anatomic niches that are susceptible to relapse 9 , but could also result in higher rates of acute graft-versus-host disease (GVHD) and increased GVHD lethality 10, 11 . Early clinical
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From trials suggest that checkpoint blockade therapy with nivolumab or ipilimumab as treatment for relapse after HSCT could be effective with a tolerable side effect profile 12, 13 . Understanding the impact of prior PD-1 blockade on both the safety and efficacy of HSCT is critical to select candidates for PD-1 blockade among patients who may be future candidates for HSCT and to select appropriate treatment strategies for
HSCT candidates who are responding to PD-1 blockade or who have relapsed after prior PD-1 blockade.
We therefore conducted an international retrospective study of patients treated with an anti-PD1 mAb at some point prior to HSCT, with the goal of describing toxicity and disease control. In addition, immune profiling analysis using flow cytometry was performed on a subset of patients with available samples pre-and post-HSCT to explore the possible basis of observed differences in HSCT outcomes.
METHODS

Patients
To develop this collaboration, we contacted centers who participated in early studies of 2015 were used as a control cohort. Blood samples from both cohorts were obtained on day 0 (prior to stem cell infusion) and 1, 2, 3, 6, 9 and 12 months after transplant.
Whenever possible, fresh samples were analyzed prospectively. When fresh samples had not been analyzed, cryopreserved samples were thawed and tested with the same panel of monoclonal antibodies. Samples obtained after relapse were not included in this analysis.
Written informed consent was obtained from all patients prior to sample collection as part of established research sample collection protocols.
A panel of directly conjugated monoclonal antibodies was used to define functionally distinct T cell subsets, as previously described 14 . 
Statistical Considerations
Patient baseline characteristics and immunophenotype data were analyzed descriptively.
Endpoints of interest included overall survival (OS), progression-free survival (PFS), relapse, non-relapse mortality (NRM), as well as acute and chronic GVHD. OS was defined as the time from stem cell infusion to death from any cause. Patients who were alive or lost to follow-up were censored at the time last seen alive. PFS was defined as the time from stem cell infusion to disease relapse, progression or death from any cause, whichever occurred first. Patients who were alive without disease relapse or progression were censored at the time last seen alive and progression-free. OS and PFS were calculated using the Kaplan-Meier method and the log-rank test was used for comparisons of Kaplan-Meier curves. Cumulative incidence curves for non-relapse death, relapse with or without death and GVHD were constructed in the competing risks framework considering relapse, NRM and death or relapse without developing GVHD, respectively, as competing events. All time to events were measured from the date of stem cell infusion. The difference between cumulative incidence curves in the presence of a competing risk was tested using the Gray method 15 . 
RESULTS
Patients
A total of 39 patients who were treated with PD-1 blockade prior to HSCT (4 in combination with the anti-CTLA-4 mAb ipilimumab) were included in this analysis.
Baseline characteristics are summarized in Table 1 
Survival and Relapse
Median follow-up for survivors was 12 months (range, 2-33 months). Overall, the 1-year OS and PFS were 89% (95% CI, 74-96) and 76% (95% CI, 56-87), respectively, while the 1-year cumulative incidences of relapse (CIR) and NRM were 14% (95% CI, For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From and 11% (95% CI, 3-23), respectively ( Figure 1 and Table 2 ). Among the 31 patients with HL, 1-year OS, PFS, CIR and NRM were 90% (95% CI, 71-97), 74% (95% CI, 50-88), 16% (95% CI, 3-36) and 10% (95% CI, , respectively ( Table 2 ).
Toxicity
The one-year cumulative incidences of grade 2-4, grade 3-4, and grade 4 acute GVHD were 44%, 23%, and 13%, respectively with a median day of onset of 27 days. The 1-year cumulative incidence of chronic GVHD was 41%. The rates of GHVD were similar for the HL cohort ( Table 2 ). There were 4 treatment-related deaths -3 from acute GVHD arising within 14 days of HSCT and one from hepatic SOS ( Table 2 Three patients (8%) developed severe hepatic sinusoidal obstruction syndrome (SOS) despite RIC. All three were treated with defibrotide and 2 required central veno-venous hemofiltration, with one fatality 51 days after transplant (patient 14, see Table 2 ). The third patient who developed severe SOS received corticosteroids in addition to defibrotide and recovered rapidly and completely.
In addition, 7 patients (18%) developed a prolonged febrile syndrome beginning 1 to 7 weeks after HSCT with elevated transaminases in 3 patients and rash in 4 patients ( Figure   3 ). Only 1 of 7 patients met Spitzer criteria and 3 of 7 patients met Maiolino criteria for engraftment syndrome 16, 17 . All patients were started on corticosteroids (~1mg/kg) within 3 weeks of fever onset. Two patients with this syndrome (patients 3 and 8) developed severe, fatal acute GVHD shortly after the onset of fevers, as described above. Of the remaining 5 patients, 4 required prolonged steroid courses for management of recurrent fevers, rash, or LFT abnormalities ( Figure 3 ). Two of those four patients developed clear chronic GVHD while on a steroid taper.
Clinical predictors of GVHD, survival, and NRM
PD-1 dosing and timing
Patients who received greater than or equal to 8 doses (the median value in this cohort) of PD-1 blockade appeared to have improved PFS at one year compared to those receiving less than 8 doses (91% (95% CI 70-98) vs. 54% (95% CI 25-76) p=0.039). A slightly larger proportion of these patients had a CR at the time of HSCT, but the difference was not significant (69% vs 54%, p=0.5). No significant differences were seen in one-year 1 1 rates of OS (95% (95% CI 72-99) vs. 77% (95% CI 44-92) p=0.064), CIR (4% v 23%, p=0.4), and NRM (5% v 23%, p=0.070) when stratified by total doses of PD-1 (8 or more doses versus less than 8 doses). Duration of time between the last dose of PD-1 blockade and HSCT (greater than 60 days vs. less than 60 days) did not significantly affect oneyear rates of OS, PFS, CIR, NRM or the incidence of GVHD or febrile syndrome.
The four patients treated concurrently with ipilimumab and a PD-1 inhibitor all developed acute GVHD, including one fatal case of grade IV acute GVHD. The 6-month rate of grade 3-4 acute GVHD was higher in these patients compared to those treated with PD-1 blockade alone (75% vs. 17% p=0.010). There were no significant differences seen in 1-year OS (75% vs. 91% p=0.3), 10 month PFS (75% vs. 80% p=0.13), 10 month CIR (0% vs. 11% p=0.4), 10m NRM (25% vs. 9% p=0.3), or 1-year incidence of chronic GVHD (25% vs. 43%, p=0.8).
Donor and graft characteristics
Among patients receiving bone marrow grafts, rates of grade 3-4 acute GVHD were lower compared to patients receiving PBSCs (0% vs. 32%, p=0.036), but this did not result in a significant difference in chronic GVHD, NRM, or survival. There were no significant differences in outcomes based on donor source (ie matched vs unmatched).
Among the 14 patients undergoing haploidentical donor transplants, 1-year OS, PFS, CIR and NRM were similar to the entire cohort (OS 93% (95% CI, 59-99), PFS 70% (95% CI, 30-90), CIR 23% (95% CI, 2-56) and NRM 7% (95% CI, 0-28)). Likewise there were no significant differences based on GVHD prophylaxis regimen, treatment with a salvage Immune reconstitution after HSCT Seventeen of 19 patients who underwent HSCT at DFCI/BWH had blood samples available and were included in a subgroup analysis. Twenty-four patients treated with RIC HSCT during the same time period were assembled as a control cohort. They were matched as able for disease, conditioning intensity, sex, and GVHD prophylaxis regimen (Supplemental Table) 
DISCUSSION
Preclinical studies have suggested that immune activation from checkpoint blockade could lead to both increased immune-related toxicity and anti-tumor activity [9] [10] [11] . Our results strongly support the hypothesis that prior checkpoint blockade affects HSCT outcomes, based on several aspects of this cohort. In terms of toxicity, we observed a higher-than-expected rate of early severe transplant-related complications. While the overall incidences of acute and chronic GVHD did not appear very different from that expected in a population of patients undergoing T-cell replete RIC HSCT for lymphoma, the incidence of grade 4 acute GVHD appears higher than prior studies (13% vs 3-4%) 18, 19 ; in addition, the 3 patients who succumbed to GVHD developed a particularly rapid and virulent form of acute GVHD which is rare after RIC HSCT. These early deaths prompted an FDA label warning for use of HSCT after prior PD-1 blockade. In further support of the possible role of prior checkpoint blockade, the liver biopsy of one of the patients with fatal GVHD (Figure 2 ) provides histologic evidence of both GVHD and drug-induced hepatitis, strongly suggesting that prior checkpoint blockade may have magnified the severity of liver injury. In addition, severe SOS is a rare event in the RIC setting, and the rate of severe SOS in this cohort appeared greater than that seen in a prior 1 4 large retrospective series of RIC allogeneic transplants (8% vs 2.1%) 20 We also report an atypical non-infectious febrile syndrome that occurred in a sizeable minority of patients.
The majority of these patients did not meet criteria for engraftment syndrome and required much longer courses of steroid treatment than is typically seen in engraftment syndrome. The syndrome also appeared to be distinct from reports of cytokine-release syndrome (CRS) in patients receiving post-transplant cyclophosphamide (PTCy) after a haploidentical PBSC. None of the seven patients we report received PTCy after a haploidentical PBSC and the onset of fevers is delayed in our cohort (median 15 days; range 6-47 days) compared to those reported with CRS which occurred with 72 hours of HSCT 21 . As many of these patients went on to develop GVHD, this febrile syndrome may lie on the same immunologic/inflammatory spectrum as GVHD. Prospective assessment with measurements of cytokines and immune activation is needed to better define this phenomenon.
Despite these toxicities, the rate of NRM was not appreciably higher than previously published series in similar patient populations [22] [23] [24] [25] . Furthermore, HSCT after PD-1 blockade may be associated with lower-than-expected relapse rates. CIR at one year in this study compares favorably to that expected for this cohort based on the Disease Risk Index mix of patients (14% vs 26%) 26 . Among the HL subgroup, the one-year relapse rate appears lower than that observed in many historical series of HL patients undergoing RIC allogeneic transplant (16% vs 26-41%) 18, 19, 22, 24, 27 , however patients in most of these series likely had a higher disease burden at the time of HSCT compared to our cohort.
Rates of relapse were similar to that seen in one small phase II trial of RIC for HL in
which patients had a comparable rate of CR prior to transplant 28 . Clearly longer-term follow-up of larger populations is necessary (which is ongoing, as we continue to expand this collaboration and follow the patients included). Nonetheless, our results at least lend credence to a possible accentuation of GVT by prior PD-1 blockade.
Immune profiling of circulating T-cell subsets also supports an immunologic difference in patients treated with PD-1 blockade. While it was not possible to create a control cohort for this analysis that was perfectly matched with respect to all possible salient characteristics (e.g., age, disease, sex, donor, graft source, GVHD prophylaxis), we observed clear patterns of differences in immune reconstitution after PD-1 exposure that warrant additional investigation. Specifically, the increased rates of early immune complications and potentially decreased relapse rates may be due to imbalanced T cell recovery after transplantation. Prior checkpoint blockade therapy did not appear to affect the overall recovery of CD4 or CD8 T cells after transplant, but patients treated with anti-PD-1 mAbs had a decreased Treg:CD4Tcon ratio at 0 and 1 months after transplant and a decreased Treg:CD8 ratio at 0, 1, and 2 months after HSCT when compared to matched controls ( Figure 4) . In prior studies, a ratio of Treg:CD4Tcon cells of less than 9% predicted both increased incidence and severity of acute GVHD, and the ratio was 3-5% in our PD-1 cohort vs. 10-11% in controls 29, 30 . Additionally, decreased Treg:CD4Tcon ratios may also predict an augmented GVT effect as observed in a trial of ipilimumab for relapse after HSCT where there was a trend among clinical responders of lower Treg:CD4Tcon 13 .
For While the associations we examined are only hypothesis-generating in nature and in no way intended to support definitive conclusions, they suggest that patients receiving PD-1 blockade who are considering allogeneic HSCT could possibly benefit from receiving at least 8 doses of a PD-1 inhibitor, when clinically possible; this hypothesis should be validated in future studies. Additionally, we observed a dramatic decrease in the rate of severe acute GVHD among patients receiving BM compared to PBSC grafts. This pattern has been reported previously, but to a lesser degree than our preliminary findings 39 .
While rates of NRM and PFS were not significantly reduced among recipients of BM grafts, this approach may be beneficial for GVHD control. We also noted significantly higher rates of acute GVHD in patients who received combined therapy with ipilimumab and PD-1 blockade prior to HSCT, suggesting that HSCT in such patients likely carries increased risk and should be performed cautiously. Additional studies of a larger patient cohort are clearly needed to validate and refine these findings. 1 8 We acknowledge that this analysis has several limitations. In order to report all known cases of allogeneic HSCT after prior PD-1 therapy, we included patients regardless of their transplant regimens. The heterogeneity of transplant strategies makes interpretation of subset analyses more challenging. While we directly contacted all centers involved in the early phase studies of PD-1 inhibitors for lymphoma, the growing use of PD-1 blockade on-and off-label makes it impossible to include all patients worldwide who received HSCT after PD-1 blockade. We therefore acknowledge the possibility of selection bias in reporting patient outcomes, although our recruitment strategy, which was center-based rather than patient-based, should effectively minimize this bias. Lastly, the control cohort for the immune reconstitution analysis was older and could not be perfectly matched for all important transplant-related variables, as discussed above.
There are currently many questions regarding the role and appropriateness of HSCT after PD-1 blockade. The sample size and follow-up of this study are limited, which precludes examination of long-term outcomes and limits our ability to study predictive markers of efficacy or toxicity. Despite these limitations, with a one-year PFS of over 75% in a population of heavily pre-treated patients with advanced disease, our study does demonstrate that HSCT after PD-1 blockade is feasible in appropriately selected patients and may be associated with increased immune toxicity but also good disease control. We conclude that prior PD-1 blockade should not be considered a contraindication to HSCT in this patient population.
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